|
Protein Degraders of NSD2 for Targeted Treatment of Head and Neck Cancers
SHORT DESCRIPTION
Targeted protein degraders that selectively eliminate NSD2 for improved treatment of head and neck cancers.
INVENTORS
Gary Schiltz*
Weinberg College of Arts and Sciences, Department of Chemistry
Yanis Boumber
* Principal Investigator
NU Tech ID: NU 2023-140
IP STATUS
U.S....
Published: 6/16/2026
|
Updated: 6/16/2026
|
Inventor(s):
Keywords(s): BIO2026, Cancer/Oncology, Head and neck cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and neurodegenerative disorders
NU 2016-137B
INVENTORS
Richard Silverman
Weinberg College of Arts and Sciences, Department of Chemistry
SHORT DESCRIPTION
Novel highly selective neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and other cancers with high expression of nNOS (e.g., gliomas, ovarian cancer) as well as neurodegenerative...
Published: 6/17/2026
|
Updated: 6/16/2026
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, ALS - Amyotrophic Lateral Sclerosis, AUTM26C1, BIAUTM1, BIO2026, Cancer/Oncology, HD - Huntington's Disease, Melanoma, Neurodegenerative disease, Neuroinflammation, Neurologic disease, nNOS, PD - Parkinson's Disease, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Biomimetic HDL Nanoparticles for Treatment of Cancer, Immune and Inflammatory Disorders, and Cardiovascular Disease
SHORT DESCRIPTION
Self-assembling biomimetic high-density lipoprotein nanoparticle (HDL NP) platform technology with a soft organic core, designed to more closely replicate key functional properties of mature human HDL for therapeutic use in cardiovascular disease, cancer, and inflammatory/immune disorders.
INVENTORS
Colby Thaxton*
Northwestern...
Published: 7/1/2026
|
Updated: 6/16/2026
|
Inventor(s):
Keywords(s): Atherosclerosis, Autoimmune disease, BIO2026, Breast cancer, Cancer/Oncology, Cardiology and Cardiovascular disease, Gene therapy, Immunology, Immunotherapy, Inflammation, Nanomaterials, Nanoparticle, Nanotechnology, Nucleic Acids, Platform technology, Prostate cancer, Research tool, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Biomarkers & Biomedical Research Tools, Life Sciences > Healthcare Devices, Tools & IT, Life Sciences > Therapeutics
|
|
Novel Aminotransferase Inhibitor Platform for the Treatment of Cancer and Neurological Disorders
SHORT DESCRIPTION
Novel Aminotransferase Mechanism-Based Inhibitor (MBI) Platform Targeting OAT and GABA-AT as Novel Treatments for Cancer and Neurological Disorders.
INVENTORS
Richard Silverman*
Weinberg College of Arts and Sciences, Department of Chemistry
* Principal Investigator
DEVELOPMENT...
Published: 6/17/2026
|
Updated: 6/1/2026
|
Inventor(s):
Keywords(s): AD - Alzheimer’s Disease, BIO2026, Cancer/Oncology, CNS - Central Nervous System, Colon cancer, Epilepsy, Gastric cancer, Liver cancer, Lung cancer, Neurodegenerative disease, Neurologic disease, Neurology, Pancreatic cancer, PD - Parkinson's Disease, Psychiatric disorder, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Fatty-Acid Modified Cytotoxins and Peptides for Improved Efficacy, Safety, and Dosing Flexibility
SHORT DESCRIPTION
A suite of four complementary technologies for a long-chain fatty‑acid–guided drug delivery platform to achieve superior therapeutic outcomes with reduced toxicity across both oncology and critical care applications.
INVENTORS
Nathan Gianneschi*, and others
Weinberg College of Arts and Sciences,...
Published: 6/2/2026
|
Updated: 6/1/2026
|
Inventor(s):
Keywords(s): Adjunct therapy, BIO2026, Biologic, Breast cancer, Cancer/Oncology, Chemotherapy, Colon cancer, Lung cancer, Ovarian cancer, Pancreatic cancer, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Small Molecule Inhibitors of Pleckstrin-2 for Treating Myeloproliferative Neoplasms
SHORT DESCRIPTION
Small molecule inhibitors of Pleckstrin-2 (Plek2) for treating cell proliferative diseases and disorders, particularly myeloproliferative neoplasms (MPNs).
NU Tech IDs: NU 2018-169, NU 2021-005
PRINCIPAL INVESTIGATOR
Peng Ji
Northwestern University Feinberg School of Medicine, Department of Pathology
IP...
Published: 5/27/2026
|
Updated: 5/27/2026
|
Inventor(s):
Keywords(s): Breast cancer, Cancer/Oncology, Colon cancer, Leukemia, Lung cancer, Pancreatic cancer, Small molecule, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Targeting Autoimmunity-Associated T cells via AHR Pathway Control
SHORT DESCRIPTION
Use of AHR agonists to inhibit pathogenic Tfh/Tph cell differentiation, potentially reducing disease activity.
INVENTORS
Jaehyuk Choi*
Northwestern University Feinberg School of Medicine, Department of Dermatology **(Now at UT Southwestern)**
Deepak Rao
Brigham and Women's...
Published: 6/16/2026
|
Updated: 5/7/2026
|
Inventor(s):
Keywords(s): Autoimmune disease, BIO2026, Immunology, Immunotherapy, Inflammation, RA - Rheumatoid arthritis, SLE - Systemic lupus erythematosus, Small molecule, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Incomplete Autophagy Induction for the Treatment of Cancer
SHORT DESCRIPTION
This incomplete autophagy inducer triggers caspase-mediated apoptosis in cancer cells by inducing incomplete autophagy, leading to tumor reduction and improved survival.
INVENTORS
INVENTORS
Maciej Lesniak*
Northwestern University Feinberg School of Medicine, Department of Neurological Surgery
Jawad...
Published: 6/16/2026
|
Updated: 5/7/2026
|
Inventor(s):
Keywords(s): Autophagy, BIO2026, Brain cancer, Breast cancer, Cancer/Oncology, Lung cancer, Melanoma, Repurposed Drugs, Small molecule, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Once-Weekly Glucocorticoid Steroid Dosing for Enhanced Muscle Function and Metabolic Health
SHORT DESCRIPTION
A glucocorticoid regimen that preserves the benefits of steroids on muscle mass and function while mitigating many of the metabolic and growth‑related toxicities seen with daily dosing in various inflammatory, autoimmune, respiratory, and neuromuscular disease settings.
INVENTORS
Elizabeth McNally*, MD, PhD
Northwestern...
Published: 6/16/2026
|
Updated: 5/7/2026
|
Inventor(s):
Keywords(s): Aging, BIO2026, DMD - Duchenne muscular dystrophy, Immunology, Inflammation, Metabolic disorders, Muscle metabolism, Rare diseases, Small molecule, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Dual-Action Inhibition Strategy for KRAS and LKB1 Mutant NSCLC
NU 2023-113
INVENTORS
Lillian Eichner (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)*
Reuben Shaw (Salk Institute)
SHORT DESCRIPTION
A dual drug combination to target KRAS and LKB1 mutant non–small cell lung cancer that results in superior efficacy by enhancing T cell recruitment and reducing tumor burden.
BACKGROUND
Lung...
Published: 6/16/2026
|
Updated: 4/29/2026
|
Inventor(s): Reuben Shaw
Keywords(s): BIO2026, Cancer/Oncology, Lung cancer, Repurposed Drugs, Small molecule, Therapeutics
Category(s): Life Sciences > Therapeutics
|